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24 The Journal of Thoracic and Cardiobjective: Bone marrow stem cells, especially the mesenchymal stem cell subpopu-
ation, have been used to create in vitro tissue-engineered heart valves. We hypoth-
sized that autologous bone marrow cells, injected in a decellularized porcine
caffold before surgical implantation, could promote in vivo recolonization and
imit valve deterioration. We thus analyzed the effects of in situ injection of
utologous bone marrow mononuclear cells and of mesenchymal stem cells on the
utcome of xenogenic decellularized scaffolds in a lamb model.
ethods: Decellularized porcine pulmonary valves were implanted in the pulmo-
ary artery under cardiopulmonary bypass in 14 lambs after injection in the scaffold
f autologous bone marrow mononuclear cells (BMMC) group (n  7) or of
esenchymal stem cells (MSC) group (n  7). At 4 months, valve function was
valuated by echocardiography, and valves were explanted for macroscopic and
istologic analysis.
esults: Mean transvalvular and distal gradients (millimeters of mercury) were
ower in the MSC than those in the BMMC group (1.3  0.39 vs 4.24  0.91 and
.05  1.89 vs 12.02  6.95, respectively; P  .02). Histologic examination
howed significant recolonization and re-endothelialization in both groups. How-
ver, significant valve thickening and inflammatory cell infiltration were observed in
he BMMC group. By contrast, valves from the MSC group displayed extracellular
atrix and cell disposition close to those of native pulmonary valves.
onclusions: Tissue-engineered heart valves created from mesenchymal stem cells,
njected directly in a decellularized xenograft scaffold, exhibited satisfactory he-
odynamic and histologic aspects after 4 months. Further long-term studies are
eeded to demonstrate the potential of mesenchymal stem cells for clinical appli-
ation in heart valve surgery.
reating living heart tissue valve prostheses, with structural and functional
properties of native valves and without progressive deterioration after im-
plantation in young patients, remains the “grail quest” in the field of heart
alve surgery.
Xenogenic bovine pericardial and porcine valves treated with glutaraldehyde
ave been widely used as valve substitutes and remain the “gold standard” for heart
alve surgery. The porcine heart valve is a xenogenic natural scaffold, which has the
dvantage of adequate anatomic structure and unlimited availability. The glutaral-
ehyde treatment prevents xenorejection but totally inhibits scaffold recellulariza-
ion by autologous cells.1 Decellularization of such scaffolds may be an alterna
pproach, although potentially resulting in valve weakening.2 We have recently
emonstrated, in an ovine model, that a xenogenic valve scaffold, decellularized
vascular Surgery ● August 2007
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EThrough a nonenzymatic process,3,4 had a good mechanica
esistance under systemic strain. However, the scaffold only
llowed partial spontaneous recolonization by host cells
fter implantation in vivo.5,6
Scaffold recolonization by autologous cells before im-
lantation seems a relevant strategy to obtain a fully recol-
nized living autologous valve. Several groups have dem-
nstrated that in vitro seeding of cells on artificial scaffolds
r on natural matrices in a biomimetic environment suc-
eeded in the generation of functional tissue-engineered
eart valves.7-9 However, this in vitro culture step is deli
nd requires sophisticated devices and methods.
We hypothesized that this step was not necessary and
hat direct injection of autologous cells into a decellularized
enogenic scaffold, immediately before surgical implanta-
ion, could induce in vivo recolonization. In the field of
yocardial infarction and cell therapy, cells are usually
njected directly into or near the target.10 To our knowledge
uch a possibility has not yet been investigated in the field
f tissue-engineered heart valves.
The best cell candidate for such strategy is not known.
ells from various origins, either differentiated vascular
tructures11,12 or more recently newborn cord– deriv
ells,13 have been used for this purpose. Bone mar
eems a more easily available source of autologous multi-
otent lineage cells. Nonselected bone marrow mononu-
lear cells (BMMCs) have been successfully used in animal
odels and in humans to promote revascularization and
mprove healing after myocardial infarction and limb isch-
mia.14,15 The nonhematopoietic subpopulation of mese-
hymal stem cells (MSCs) contains progenitors able to
ifferentiate into valvular cells such as myofibroblasts and
ndothelial cells.16 In vitro seeding of MSCs on bioabso-
ble polymers has already been demonstrated to generate
unctional heart valves,17 which were successfully tested 
ivo in a lamb model.18 In addition, MSCs have the pote-
ial advantage to suppress many immune cell functions and
o decrease immune-mediated reactions.19,20
We thus investigated the effects of autologous BMMC or
SC injection in decellularized pulmonary porcine valve
Abbreviations and Acronyms
DPPV  decellularized porcine pulmonary valve
HBSS  Hanks balanced salt solution
BMMC bone marrow mononuclear cell
MSC mesenchymal stem cell
VTI  velocity time integral
VWF  von Willebrand factorcaffolds immediately before implantation in a lamb model. i
The Journal of Thoracicaterials and Methods
ampling and Decellularization of Porcine
ulmonary Conduits
ulmonary valve conduits were sampled from pigs (Large
hite/Landrace, 10 –15 kg of body weight). The animals were
nesthetized by intravenous injection of propofol, 20 mg/kg,
nd sufentanil, 1 g/kg. After median sternotomy, the heart was
xplanted under surgical conditions. Pulmonary valve conduits
ere harvested with a thin ridge of subvalvular muscle tissue
roximally and a short arterial segment distally. Then porcine
alve conduits were calibrated with a Hegar dilatator, weighed,
nd washed in Hanks balanced salt solution (HBSS) plus aprotinin
10 KIU/mL), penicillin (100 U/mL), streptomycin (100 g/mL),
nd nystatin (100 U/mL) plus N-2-hydroxyethylpiperazine-N-2-
thanesulfonic acid (10 mmol/L) at pH 7.6. Valve conduits were
ecellularized through a nonenzymatic procedure, associating hy-
otonic shock and low-concentration ionic detergent, as previously
escribed.3,4
In brief, valve conduits were incubated at 20°C during constant
tirring in hypotonic buffer (Tris, 10 mmol/L; ethylenediaminetet-
aacetic acid, 0.1%; and aprotinin, 10 KIU/mL; pH 8) for 14 hours
nd hypotonic buffer with sodium dodecylsulfate (0.1%) for 24
ours, washed in isotonic buffer (Tris, 50 mmol/L; NaCl, 0.15
ol/L; ethylenediaminetetraacetic acid, 0.1%; aprotinin, 10 KIU/
L; pH 8) 3 times an hour, and then immediately implanted in
ambs. In all valves, sterility controls were realized on the last
ashing solution.
one Marrow Sampling and Cell Preparation
ourteen lambs (Romanov/Ile de France; median age 12 weeks)
ere operated on in this study. Bone marrow sampling was
erformed the day before thoracotomy in the BMMC group and
week before in the MSC group. General anesthesia was
nduced and maintained by intravenous injection of propofol,
0 mg/kg, and sufentanil, 1 g/kg. Autologous bone marrow
spiration (80 mL) was performed in the iliac crest of the lamb,
nd cells were seeded in culture medium containing adenine
itrate dextrose, RPMI 1640 (Gibco BRL, Life Technologies,
nc, Rockville, Md), and heparin. BMMCs were selected
hrough a density gradient (density 1.077 g/mL) and were either
tored for 24 hours at room temperature in RPMI 1640 until
njection in valve scaffold (BMMC group) or were further
ultured to obtain MSCs (MSC group). In brief, mononuclear
ells were washed twice with Iscove’s modified Dulbecco’s
edium (1000 g, 10 minutes) and seeded at a density of 6
ells/mL in Mesencult medium (StemCell Technologies Inc)
upplemented with 100 U/mL penicillin, 100 g/mL strepto-
ycin, and 2 mol/L L-glutamine in 75 cm2 T-flasks. Cultures
ere maintained in a humidified atmosphere with 5% carbon
ioxide at 37°C. At 80% confluence, cells were washed twice in
BSS buffer and then were detached with 0.25% trypsin–
thylenediaminetetraacetic acid (Sigma Chemical Co, St Louis,
o) and resuspended in phosphate-buffered saline solution
efore injection in the scaffold. From the bone marrow aspirate,
00  50.106 BMMCs were obtained, which led to a m
mount of 7.7  3.106 MSCs after 7 days of culture. Viabi
f the cells (Trypan blue dye exclusion) was greater than 92%
n all cases.
and Cardiovascular Surgery ● Volume 134, Number 2 425
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4
ETImmediately before surgical valve implantation, all the avail-
ble cells were injected (2 mL) into each animal via a right-angled
7-gauge needle, as described by Menasche and associate10
hich allowed the creation of channels in a blisterlike pattern.
ells were injected into the pulmonary arterial wall and into the
nnulus of pulmonary valve and not into the leaflets (Figure 
oth groups, 2 animals received BMMCs or MSCs labeled with a
uorescent green marker (PKH67) to track early cell migration in
he matrix, at day 1 and day 7 postoperatively.
MMC and MSC Characterization
njected BMMCs and MSCs were identified after centrifugation
nd coloration with May–Grunwald–Giemsa stain and by immu-
ocytochemical analysis with a monoclonal mouse anti-vimentin
ntibody (1/500, clone V9; DAKO Corporation, Carpinteria,
alif), respectively (Figure 1). In addition, MSCs were chara
zed through their potential for adipogenic and osteogenic differ-
ntiation (Figure 2). In brief, for adipogenic differentiation, M
t 80% confluence were washed twice in HBSS buffer and then
ultured in Adipogenic Mesencult medium (StemCell Technolo-
ies) supplemented with 100 U/mL penicillin and 100 g/mL
teptomycin. After 2 weeks, adipocytes were stained with oil red O
Sigma). Cells were fixed in a buffered 4% paraformaldehyde
olution and incubated with 60% isopropylic alcoohol for 5 min-
tes. Oil red O was added to the cells for 10 minutes. Cells were
igure 1. A, Representative examples of bone marrow mononu-
lear cells (BMMC) after May–Grunwald–Giemsa staining (orig-
nal magnification 100). B, Mesenchymal stem cell (MSC) after
mmunocytochemical analysis with a monoclonal mouse anti-
imentin antibody (original magnification 40). C, Decellularized
orcine pulmonary valve has been reversed on a Hegar dilatator.
njection of the stem cells in the inner side of the pulmonary
rterial wall with a customized right-angled 27-gauge needle
esigned specifically to allow the creation of channels in a
listerlike pattern. The arrows indicate the first injection site.
nnulus, pulmonary annulus; Leaflet, free margin of a pulmonary
eaflet.ashed in 60% isopropylic alcohol for 5 minutes and rinsed in B
26 The Journal of Thoracic and Cardiovascular Surgery ● Augun
istilled water before counterstaining with Gill’s hematoxylin
Vector Laboratories, Inc, Burlingame, Calif).
For osteogenic differentiation of MSCs, MSCs at 80% conflu-
nce were washed twice in HBSS buffer and then cultured in
steogenic Mesencult medium (StemCell Technologies) supple-
ented with 108 mol/L dexamethasone, 50 g/mL ascorbic acid,
.5 mmol/L -glycerophosphate, 100 U/mL penicillin, and 100
g/mL steptomycin. The medium was replaced every 3 days. After
weeks, osteogenic cells were stained with silver by the method
f von Kossa. Cells were fixed in a buffered 4% paraformaldehyde
olution and then stained with 5% silver nitrate (Sigma) for 2
inutes in the darkness and then under a 60-W lamp for 30
inutes. Cells were washed 4 times in distilled water before
ounterstaining with Gill’s hematoxylin.
tudy Design and Surgical Procedure
decellularized porcine pulmonary valve (DPPV) was implanted
n the pulmonary trunk of each lamb under cardiopulmonary
ypass. Seven animals received a DPPV injected with autologous
igure 2. Characterization of ovine MSC (magnification 20);
dipogenic and osteogenic differentiation. A, Ovine MSC after
-day culture. Left column: B, Adipogenic differentiation; C, intra-
ytoplasmic accumulation of lipid stained with oil red O. Right
olumn: B, Osteogenic differentiation; E, calcium stained with
on Kossa method.MMC and 7 animals a DPPV injected with autologous MSC.
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ETIn all animals general anesthesia was induced and maintained
s described above. The pulmonary trunk was exposed through a
eft anterolateral thoracotomy entering through the fourth intercos-
al space. Two 4–0 purse strings were performed at the level of the
ortic arch and around the right appendage. Under complete hep-
rinization, cardiopulmonary bypass (COBE Optimin oxygenator,
OBE Cardiovascular, Inc, Arvada, Colo) was established be-
ween the right atrium and the aortic arch at normothermia. With
he heart beating, the pulmonary trunk was transected, the native
ulmonary valve was resected, and the DPPV was inserted with 2
nd–to–end 4–0 running sutures. On completion of the operation,
eparin was reversed with protamine (200 UI/kg). The chest was
losed in layers, and a chest tube was inserted. The chest tube was
emoved after extubation. Animals were then settled in standard
onditions, with food and drink ad libitum. All animals received
000 mg of ceftriaxone and 500 mg of aspirin for the first post-
perative week on a daily basis. For pain control, during the first
operative days, a transdermal fentanyl patch was applied on the
hest. All the animals received humane care in compliance with
he “Guide for the Care and Use of Laboratory Animals” published
y the National Institutes of Health.
chocardiography
wo-dimensional Doppler echocardiography was performed with
Vingmed CFM 800 echocardiograph (General Electric Com-
any, Fairfield, Conn) and a 5-MHz transducer by the same qual-
fied echocardiographer who was blinded to the surgical status of
he animals. The parasternal long-axis view was used to measure
eft ventricular end-systolic and end-diastolic diameter, left ven-
ricular thickness, left ventricular fractional shortening, and left
entricular ejection fraction. The parasternal short-axis view was
sed to measure the diameter of the right ventricular outflow tract.
elocities time integrals (VTI) were determined at the level of the
ight ventricular outflow tract and at the level of the prosthesis,
espectively, by pulsed and continuous-wave Doppler. Mean and
eak transvalvular and transanastomotic gradients (ie, distal gra-
ients) were derived with the modified Bernoulli equation. The
oppler velocity index was determined by the ratio of the VTI
cross the valve and in the right ventricular outflow tract (RVOT).
ffective orifice area was determined by the continuity equation:
Doppler velocity index  RVOT diameter2  )/4. Cardiac
utput was computed as the product of right ventricular stroke
olume (VTI in the RVOT  RVOT diameter2   /4) and heart
ate. Echocardiographic evaluation was performed at seventh post-
perative day and at the time of planned death.
alve Follow-up and Explantation Process
n each group, 1 lamb was put to death at day 1 and another at day
postoperatively for fluorescent cells tracking. The remaining
nimals were put to death 4 months after implantation. The same
rotocol of analgesia and anesthetic procedures as for implantation
as used to put the animals to death humanely.
alve Analysis
xplanted valve conduits were grossly examined. Thickness, mo-
ility, and retraction of the cusps and the presence of visible
alcifications were reported. Then, fragments from the grafted
onduit were sampled for histologic analysis. Samples were fixed f
The Journal of Thoracicn a buffered 4% formaldehyde solution, dehydrated, and embed-
ed in paraffin, and sections (6 m) were stained by Masson’s
richrome and von Kossa stains for calcium detection. In addition,
amples were fixed in a buffered paraformaldehyde solution, de-
ydrated, embedded in OCT (methylmetacrylate), and frozen in
sopentane at 80°C. Immunostaining was realized on 7-m
rozen sections with monoclonal antibody against -actin
monoclonal clone ASM-1, Cymbus Biotechnology Ltd [East-
eigh, Southampton, United Kingdom], dilution 1/40 one night
t 4°C) or with polyclonal antibody against von Willebrand
actor (VWF) (polyclonal clone, Dako, dilution 1/500, 2 hours at
oom temperature) or with antibody to CD68 (monoclonal clone
BM-11, Dako, 1/50, 1 hour at 37°C), and respective isotope-
atched immunoglobulin G control (Cymbus Biotechnology). The
mmunoreaction was detected with avidin–biotin performed com-
lex peroxidase. The tissue sections were analyzed by 2 indepen-
ent observers who where blinded for animal group allocation.
tatistical Analysis
ontinuous variables were expressed as mean  SD and were
ompared by the Mann–Whitney U test and the Wilcoxon test for
npaired and paired data, respectively. Analyses were performed
ith SPSS 11.0 (SPSS Inc, Chicago, Ill).
esults
n the 4 animals that had received fluorescent-labeled cells,
arly explantation showed that at day 1 PKH67-stained cells
eatured a linear repartition, probably corresponding to the
ite of needle injection. At day 7, a few cells displaying a
cattered disposition were identified in the matrix, in the
ascular wall, and in the leaflets. Nuclear counter coloration
ith 4=,6-diamidino-2-phenylindole showed also nonla-
eled cells in the matrix, suggesting the presence of cells
igure 3. At day 7 after surgical implantation, in both groups,
abeled cells were identified in the matrix with PKH67 (green)
A and B) and nuclear counter coloration with 4=,6-diamidino-2-
henylindole (blue) (C) and merged (D). Nonfluorescent cells from
ost origin are visible in the matrix (white arrows).rom host origin (Figure 3).
and Cardiovascular Surgery ● Volume 134, Number 2 427
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4
ETEarly echocardiography (postoperative day 7) showed no
alve failure and no significant difference between the 2
roups. The results of early and late (4 months) echocardi-
graphy are shown in Table 1. No significant pulmonary
egurgitation was recorded in either group at any time. In
he BMMC group, we observed a significant increase of
he mean transvalvular and distal gradients from day 7 to
onth 4 (P  .043 and .016, respectively) (Figure 4). 
ontrast, the gradients did not increase and even tended to
ecrease in the MSC group (P  not significant). After 4
onths, the mean gradients were significantly lower in
he MSC than in the BMMC group (P  .016). A de-
rease of the Doppler velocity index and of the effective
rifice area was found in the BMMC group as compared
ith the MSC group.
Representative gross and histologic features of the 2
roups at 4 months are shown in Figures 5 and 6. 
MMC group, the wall was thickened with calcifications,
ith a fibrous pannus covering the suture line; the leaflets
ere slightly thickened and retracted. In the MSC group, no
alcification was observed, the wall remained thin and
mooth, suture lines were not covered with fibrous pannus,
nd leaflets were thin.
In both groups, VWF staining demonstrated complete
e-endothelialization, and -actin staining demonstrated the
resence of a thin ridge of smooth muscle cells, which was
ore pronounced in the MSC group. However, important
ifferences were observed between the 2 groups with re-
pect to other histologic features.
In the adventitia of BMMC group, extracellular matrix
as disorganized, with a strong inflammatory cell infiltra-
ion, of macrophage origin (anti-CD68 staining), and many
eo-vessels were present (Masson trichrome and anti-VWF
taining). Numerous cells also infiltrated the media, mostly
f macrophage origin (anti-CD68 staining) and collagen
bers were thickened and disorganized, especially in the
ubendothelial areas. Few cells staining positively for anti–
-actin antibody were present in these areas. The leaflets
ere thickened, with the disappearance of the differential
ABLE 1. Echocardiographic data
Postoperative
BMMC (n  5) M
fficient orifice area (cm2) 1.4  0.2
oppler velocity index 0.8 0.2
ean transvalvular gradient (mm Hg) 1.5 0.8
ean distal gradient (mm Hg) 4.4 2.2
aximum transvalvular gradient (mm Hg) 2.5 1.2
aximum distal gradient (mm Hg) 6.9 3.0
MMC, Bone marrow mononuclear cell; MSC, mesenchymal stem cell.epartition of collagen between the ventricularis, the spon- s
28 The Journal of Thoracic and Cardiovascular Surgery ● Auguhe
iosa, and the fibrosa. Von Kossa staining showed calcifi-
ations in the pulmonary arterial wall.
In the MSC group, the global organization of collagen
bers was preserved, and few fusiform cells were observed
n the subendothelial area and in the adventitia. Rare
eovessels were visible in the adventitia (Masson trichrome
nd VWF staining). No inflammatory cells were found after
D68 staining. Pulmonary leaflets exhibited a typical orga-
igure 4. Early and late hemodynamic results. Early gradients
ere not significantly different between the 2 groups. In the
MMC group we observed a significant increase of the gradient
rom day 7 and month 4. In the MSC group gradient did not
ncrease and even tended to decrease. Late gradients were
After 4 months
n  5) P value BMMC (n  5) MSC (n  4) P value
 0.4 1.0 1.0 0.2 1.4  0.5 .11
 0.2 1.0 0.5 0.1 0.8  0.1 .032
 3.1 .42 4.2 0.9 1.3  0.4 .016
 2.7 .55 12.0 6.7 4.0 1.9 .032
 5.0 .69 7.5 1.9 2.01  0.8 .016
 6.0 .42 20.1 11.7 7.5 1.8 .032day 7
SC (
1.4
0.8
3.3
5.3
4.5
10.6ignificantly lower in the MSC group than in the BMMC group.
st 2007
nw
s
D
T
r
p
f
a
d
f ved
t
t
p
t
t
e
S
m
d
a
v
a
t
s
B
a
w
r
l
c
r
s
i
t
c
t
F
g
s
(
w
t
s
V
w
r
t
a
t
r
g
F
a
(
o
e
m
Vincentelli et al Evolving Technology
ET
ization in 3 layers, fibrosa, spongiosa, and ventricularis,
ith few recolonizing cells, which were positive for -actin
taining.
iscussion
his study demonstrates that in situ injection of bone mar-
ow cells into a porcine decellularized scaffold before im-
lantation enhanced the in vivo recolonization and induced
ull re-endothelialization. This original preseeding process
llowed scaffold recolonization under physiologic flow con-
itions, which have been shown to be critical to create
unctional living valves.21 Up to now, this aim was achie
hrough in vitro incubation in a bioreactor, which mimicks
he in vivo pressure–flow conditions and resulted in im-
igure 5. Results 4 months after explantation. Left column, BMMC
roup; right column, MSC group. Top row, Gross examination
howed that the arterial wall was thickened with calcification
*). A fibrous pannus was covering the suture line and the leaflets
ere thick. In the MSC scaffolds no calcification was observed,
he wall remained thin and smooth, leaflets were normal, and
uture line were not covered with a fibrous pannus. Second row,
on Kossa staining confirmed a huge calcification in the arterial
all of a BMMC group scaffold and none in the SMC group. Third
ow, Masson trichrome stain showed that the fibrillar structure of
he arterial wall was better preserved in the MSC group (right),
dventitia remained thin, and the cell infiltration was restricted to
he outer layer, as compared with the BMMC group (left). Fourth
ow, The thickness of the leaflets was increased in the BMMC
roup and remained normal in the MSC group.roved outcome after implantation in lambs.21,22 Notewor- a
The Journal of Thoracichy, in situ injection was performed only in the annulus of
he valve and in the arterial wall to avoid leaflet injury.
We compared the recolonization potential of two differ-
nt bone marrow cell populations, BMMCs and MSCs.
hort-term echocardiographic results confirmed good he-
odynamic performances in both groups, but significant
ifferences were observed after 4 months. The transvalvular
nd distal gradients significantly increased and the Doppler
elocity index significantly decreased in the BMMC group
s compared with the MSC group. Moreover, valves from
he MSC group exhibited less inflammatory reaction and
tructural deterioration than those from the BMMC group.
MMC group scaffolds exhibited marked inflammatory re-
ction with slightly thickened leaflets; some calcifications
ere found in the arterial wall. The MSC group, scaffolds
emained free of degenerative lesions with nonretracted thin
eaflets. Interestingly, in this group the suture line was not
overed with a thick fibrous pannus. All together, these
esults suggest the onset of a structural deterioration of the
caffold in the BMMC group and a protective effect of the
njection of MSCs.
Several points remain to be investigated with respect to
hese beneficial effects. We have controlled that injected
ells remained in the matrix after implantation after short-
erm explantation of the conduit (arterial wall and leaflets)
igure 6. Histochemical analysis. Top, CD68cell infiltration of the
rterial wall in the BMMC group (left) and not in the MSC group
right). Middle, Complete endothelialization in both groups dem-
nstrated by Von Willebrand factor staining. Bottom, The pres-
nce of a thin ridge of smooth muscle cells after -smooth
uscle actin staining in both groups but mostly in the MSC group.t 7 days. Interestingly, host cells were also identified close
and Cardiovascular Surgery ● Volume 134, Number 2 429
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4
ETo the injected MSCs, underlying the positive chemotactic
ffect toward migration of autologous cells. However,
hether MSCs injected in the scaffold induced in situ
ifferentiation into myofibroblasts and endothelial cells re-
ains uncertain.
MSCs are pluripotent cells present in many tissues, in-
luding bone marrow. They can differentiate into osteo-
lasts, chondrocytes, neurons, skeletal and smooth muscle
ells, and endothelial cells.16,23,24 The differentiation into
yofibroblasts and endothelial cells, as well as collagen
ynthesis, may depend on mechanical environment, as re-
ently reported.25,26 Moreover, MSCs can produce grow
actors and cytokines that play a role in their proliferation or
ifferentiation abilities.27
Alternatively, MSCs may induce the homing and dif-
erentiation of autologous cells, through a paracrine se-
retion of growth and chemotactic factors, as previously
escribed,21,28 –30 MSCs can supply a lot of angioge
ytokines allowing neovascularization. Part of these bene-
cial effects may be due to the stem cell factor pathway,
hich directly increases circulating endothelial progeni-
ors.30 In another model of dilated cardiomyopathy, 
ealing role of MSCs was directly associated with a de-
rease of the matrix metalloproteinase activities.31
In addition to their healing and angiogenic properties,
SCs induce little rejection by allogenic T cells,32 uggest-
ng that they also have immunomodulatory capabilities33,34
s demonstrated in the field of bone marrow graft-versus-
ost disease.19 Xenogenic porcine scaffolds remain an-
enic, whatever the used decellularization process, and in-
ammatory and thrombotic process against the implanted
caffold may occur.35
To our knowledge, immunoregulatory properties in the
eld of xenoimmune reactions, as suggested by our results,
ad not been investigated up to now. However, it is widely
emonstrated that immunologic outcome after MSC injec-
ion may vary according to environmental factors, and a
ecrease of immune reaction against residual xenoantigens
resent in the scaffold seems possible. On the other hand, it
hould also be underlined that selection of MSCs eliminates
lot of inflammatory cells such as granulocytes, progeni-
ors, and macrophages, as well as lymphocytes, which may
nhance the inflammatory and thrombotic reaction when
njected in a xenogenic matrix.
Some potential limitations of this study should be under-
ined. First, in this animal model, we chose a relatively short
-month observation period. However, the sheep is an ac-
epted model for testing valve prostheses and is known for
ts fast degeneration of foreign materials after implantation,
specially in the growing sheep. Flameng and associates
ave demonstrated that significant bioprosthetic degenera-
ion could be observed in first 3 months after implantati36
hus, the relatively short 4-month period we have chosen
30 The Journal of Thoracic and Cardiovascular Surgery ● Augullows relevant observation of the degeneration process.
econd, the use of MSCs in tissue valve engineering may
lso raise concerns with regard to multilineage potential of
hese cells and possible adverse reactions, such as emer-
ence of tumors in patients receiving such cells. Assessment
f the conversion of implanted MSCs to other cell lineages
nd the survival and fate of implanted cells is warranted
efore clinical applications. Given these limitations, long-
erm studies are needed to demonstrate the potential of
SCs for clinical application in heart valve surgery.
In conclusion, we have shown that matrix recellulariza-
ion was feasible in vivo without a bioreactor. This point
ill help to simplify clinical applications, because it avoids
he complex “pre-seeding step.” Autologous MSCs seem
romising cells in this setting, because they improved the
echanical behavior and the healing of a decellularized
enogenic valve. In future clinical applications, bone mar-
ow aspiration followed by selection of autologous MSCs
nd in situ injection might be realized before valvular re-
lacement. Whether this tissue-engineering approach may
e used for clinical studies warrants further long-term ani-
al studies.
This work was realized in Institut Federatif de Recherche 114,
nd supported by grants from University of Lille 2 (EA2693), from
he French Fond National pour la Science, Ministère de la Recher-
he (Action Concertée Incitative 2002-Grant 02TS 050), and from
onseil Régional Nord Pas de Calais (2003-OBJ2-2004/1-4-1, no.
57) and “ESPRI”/FEDER R04026EE. We especially thank Al-
xandre Ung for expert technical assistance and Michel Pottier and
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iscussion
r Richard D. Weisel (Toronto, Ontario, Canada). If you think
hat the major difference is related to the fact that the cells were
ultured, it is possible that they contained some of the cytokines
hat were used in the culturing process? I presume that you used
etal bovine serum as one of the cytokines. If the cytokines are the
mportant component here, perhaps you need to seed either the
ells or the acellular tissue with cytokines in addition to the cells.
hat are your thoughts?
Dr Vincentelli. We did not investigate this issue about the
ytokines precisely, but this remains a possibility. We focused
ore on the possibility that the selection of cultured MSCs could
imit the inflammatory process owint to the scaffold xenoantigens,
artly because hematopoietic stem cells were excluded from our
opulation of bone marrow stem cells. But we have not investi-
ated the effects of medium cytokines yet.
Dr Francisco Diniz Affonso da Costa (Curitiba, Brazil). We
lso have done a lot of experiments in sheep with decellularized
llografts from sheep to sheep. What we found is that there is
artial re-endothelialization and partial repopulation just with the
ecellularized allografts. We agree with you that you need to seed
ome cells, either endothelial cells and fibroblasts or maybe stem
ells, as you showed. What do you think is the best method to seed
hese mesenchymal cells in the valves? Do you just put it there and
eave it there or do you have to inject inside the wall or inside the
usps or both? What do you think is the best method to do that?
Dr Vincentelli. Thank you for your comment and your inter-
sting question. We have used the injection in the matrix with a
ery thin needle, just as used for injection of myoblasts in the
yocardium. We found that the same technique could be used for
he injection of the cells in the valve matrix. Cells were injected
nly in the arterial wall, and not in the cusps, which are too thin.
ther team used seeding in vitro in a bioreactor. We have hypoth-
sized that we could skip this step and use the animal as a
ioreactor. However, we have no direct evidence that the injected
ells will directly grow in the matrix. We hypothesize that injected
and Cardiovascular Surgery ● Volume 134, Number 2 431
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ETells might enhance the autologous recellularization and that in-
ection just before implantation is just a booster for autologous
ecellularization.
Dr Weisel. The difficulty is that you need to demonstrate that
ou have an increased survival of the implanted cells by your
echnique, because you would anticipate that if you had it in a
ioreactor for 7 days beforehand, you would have a full difference
n the number of cells that were available in the decellularized
atrix before implantation. Of course, if you think the biologic
ctivity is related to the function of those cells, they need to be
live, they need to function, they need to produce the cytokines s
32 The Journal of Thoracic and Cardiovascular Surgery ● Auguhat are most effective, and that would probably only happen if
hey had been seeded as opposed to injected immediately before
he present implantation. It is a question that will need to be
ddressed in further studies.
Are there any other questions and do you have any response?
Dr Vincentelli. I agree with your comment. We think that we
ave still a long way to go. One of the next key points will be the
ong-term labeling of new cells to evaluate their outcome. This
hould help to determine whether injected cells engraft, proliferate,
nd eventually differentiate in situ or send chemotactic and growth
ignals to other host cells.
st 2007
